


# Seconda Lezione: Interpretare il dolore


14 / 03 / 2018



Sorrow, 1882  
V. Van Gogh

*Levis est dolor qui loquitur, magnus muta*

Lieve è il dolore che parla...Il grande dolore è muto.



*Lucio Anneo Seneca (Corduba 4 a.C. – Roma 65 d. C)*

# Pain

“An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”

*IAPS, APS, 2003*

- Pain is always a subjective experience;
- Everyone learns the meaning of “pain” through experiences (usually injuries) in early life;
- Pain is a significant cause of stress

# Various types of pain

**Somatic pain:** caused by the activation of pain receptors in the skin or deeper tissues (musculoskeletal tissues)

**Visceral pain:** caused by activation of pain receptors (e.g., infiltration, compression, stretching) of the thoracic, abdominal or pelvic viscera

**Neuropathic pain:** caused by injury to the nervous system (e.g., a tumor compressing nerves or the spinal cord, or cancer actually infiltrating into the nerves or spinal cord)

# Acute vs. chronic pain

## Acute pain:

- short-lasting (up to 'several days' )
- clinically associated with diaphoresis and tachycardia
- increasing in intensity over time, or it can occur intermittently (**episodic or intermittent pain**)
- usually related to a discreet event for onset: e.g., post-operative, post-trauma, etc...

## Chronic pain:


- long-term (> 3 months)
- more subjective (less characterized than acute pain)
- more commonly associated with psychological distress
- usually affects a patient's quality of life

# Pain: How do we measure it ?




zero

max



# General features


# Pain pathways




(a) Dorsal column–medial lemniscal pathway

(b) Spinothalamic tract


# Processing of Sensory Signals in Spinal Cord, Brain Stem, and Brain




# Ascending Visceral Pain Pathway




# Descending Pain Modulation



# Convergence of Somatic and Visceral Afferents in the Spinal Cord




# Divergence of Somatic and Visceral Afferents in the Spinal Cord




(Wolf et al. 1965)

# Mackenzie's Interpretation of the mechanisms of visceral pain and related reflexes (1909)





# Colonic Referred Pain



# **Mechanism(s) of visceral pain**


# Pathways of visceral sensations



Low-threshold vagal mechanoreceptor


Splanchnic

Pelvic




Muscular-mucosal afferents

# Types of afferents in the gut







# Visceral hypersensitivity evoked by serosal (splanchnic) afferents in a mouse model of colitis



- Low-threshold mechanosensory fibers → not involved
- High-threshold (nociceptors) → acute and chronic (recovery) hypersensitivity


# **Hypersensitivity in the clinical setting**

# Visceral hypersensitivity in IBS




Whitehead W.E., et al., *Dig Dis Sci* 1980; 25(6):404-1


# Repetitive Stimulation Sensitizes the Spinal Cord



# Prevalence of rectal hypersensitivity in IBS




# Female with IBS show more hypersensitivity than male pts




*Posserud I., et al., Gastroenterology  
2007;133: 1113-23*

# Altered perception is associated with symptom severity in IBS




# **Mechanisms and sites of hypersensitivity**



# Mechanisms of visceral hypersensitivity



# Mechansims of Altered Afferent Sensitivity






# Increased TRPV1-immunoreactive sensory fibres in IBS



- 23 IBS pts; ~ 2/3 with non-D-IBS
- Low-grade inflammation
- Only TRPV1-IR nerves and MCs correlated with pain

# Colonic mucosal mediators of IBS patients excite rat mesenteric sensory neurons



Proteases mainly involved in the firing of sensory neurons in IBS

# CNS: visceral hypersensitivity



*actual* rectal distension (45 mmHg)

*expectation* rectal distension

**IBS hypersensitive**  
(n=15)

**IBS normosensitive**  
(n=18)

**controls**  
(n=18)




 fMRI activation  
 fMRI deactivation

↑ activation insula & ACC in hypersensitive vs normosensitive & controls

↑ activation insula in hypersensitive vs normosensitive

↑ activation right hippocampus in normosensitive vs controls

# Visceral and somatic hypersensitivity overlap in IBS pts




**IBS pts 2fold ↑  
of somatic comorbidities  
e.g. fibromyalgia, CFS, etc.**

*Riedel A., et al., J Psychosom Res 2008;64:573-582*

# Spinal Gating for Three Classes of Visceral Nociceptors (Low, High and Silent) Account for Normal Regulatory Functions, Acute and Chronic Pain

Synaptic terminal, second order, active neuron

Synaptic terminal, spinal and inactive neuron



# Pharmacological treatment



Non-opioid antinociceptive drugs

Opioid drugs

# Non-opioid antinociceptive drugs

Drug	Dose (mg)	Frequency of administration
Paracetamol (acetaminophen)	1000	Every 6-8 hours
Aspirin	300	Every 8 hours
Diclofenac	75	Every 8 hours
Diflunisal	500	Every 8 hours
Etodolac	400	Every 8 hours
Ibuprofen	200	Every 6-8 hours
Indomethacin	50	Every 6-8 hours
Ketoprofen	75	Every 8 hours
Ketorolac	10	Every 4-6 hours
Naproxen	500	Every 12 hours
Sulindac	200	Every 12 hours
Piroxicam	40	Once a day
Selective COX-2 inhibitors <ul style="list-style-type: none"> <li>• Celecoxib</li> <li>• Etoricoxib</li> </ul>	200 120	Every 12 hours Once a day

# Paracetamol

- First choice in mild-moderate pain

Dose:

**1 g x 4 / day**

Hepatopathy / altered hepatic function:


**1 g x 3 / day**

- No cross-reaction with NSAIDs

# NSAIDs

Drug	Dose (mg)	Frequency of administration
Aspirin	300	Every 8 hours
Diclofenac	75	Every 8 hours
Diflunisal	500	Every 8 hours
Etodolac	400	Every 8 hours
Ibuprofen	200	Every 6-8 hours
Indomethacin	50	Every 6-8 hours
Ketoprophen	75	Every 8 hours
Ketorolac	10	Every 4-6 hours
Naproxen	500	Every 12 hours
Sulindac	200	Every 12 hours
Piroxicam	40	Once a day
<b>Selective COX-2 inhibitors</b> <ul style="list-style-type: none"> <li>• Celecoxib</li> <li>• Etoricoxib</li> </ul>	200 120	Every 12 hours Once a day

# Mechanisms of action of NSAIDs



# NSAIDs

- Pain related to inflammation

- DICLOFENAC: no antiplatelet action
- IBUPROFEN: lowest gastrolesivity
- KETOROLAC: highest gastrolesivity

# Non-opioid antinociceptive drugs

Drug	Dose (mg)	Frequency of administration
Aspirin	300	Every 8 hours
Diclofenac	75	Every 8 hours
Diflunisal	500	Every 8 hours
Etodolac	400	Every 8 hours
Ibuprofen	200	Every 6-8 hours
Indomethacin	50	Every 6-8 hours
Ketoprophen	75	Every 8 hours
Ketorolac	10	Every 4-6 hours
Naproxen	500	Every 12 hours
Sulindac	200	Every 12 hours
Piroxicam	40	Once a day
Selective COX-2 inhibitors		
• Celecoxib	200	Every 12 hours
• Etoricoxib	120	Once a day



PPIs to prevent  
gastropathy




PPIs not strictly  
necessary;  
cautiously  
administered  
in pts with  
previous CAD




# Opioid use and prescriptions

## Increased use of opioids



## Indications for opioid prescribing



- In 2012, >240 million prescriptions for opiate analgesics in the USA
- ~40-80% of pts take opioids for chronic, non-cancer pain
- Up to 94% of patients with advanced illness who take opioids require laxatives
- Standard laxatives are often insufficient for treatment of OIC and fail in ≈50% of cases

Camilleri M., *Am J Gastroenterol.* 2011;106(5):835-42; IMS Health 2012 (reported by Fauber J. J Sentinel. March 6, 2013);

Holzer P., *Eur Rev Med Pharmacol Sci.* 2008; 12 (S1): 119-127;6

# Opioid System

- Endogenous opioids:

- Dynorphins
- $\beta$  endorphins
- Enkephalins



Receptors:

- $\mu$
- $\delta$
- $\kappa$
- $\sigma$

CNS

PNS

ENS



- Effects:

- Euphoria
- Analgesia
- Sedation
- Relief from diarrhea
- Cough suppression

- Localization & Function in the ENS:

- Enteric neurons
- Smooth muscle cells
- Immune cells
- GI motility & secretion
- Immune response

# Opioids

Opioid	Half life (h)	Onset (h)	Duration (h)	Relative potency	Initial dose (mg)	Dosing interval (h)
<b>Pethidine / Meperidine</b> (Demerol)	2-3	0.1-0.4	1-3	0.1	50-150	4
<b>Codeine</b>	3	0.25-1.0	3-4	0.15	30-60	4
<b>Hydromorphone</b> (Jurnista)	2-3	0.3-0.5	2-3	4	2-4	4
<b>Oxycodone</b> (Oxycontin)	2-3	0.5	3-6	1.5	5-10	6
<b>Methadone</b> (Dolophine, Eptadone)	15-30	0.5-1.0	4-6	3	20	6-8
<b>Propoxyphene</b> (Darvon, Darvocet)	6-12	1.0-2.0	3-6	0.15	100	6
<b>Tramadol</b> (Contramal, Ultram)	6-7	1.0-2.0	3-6	0.1	50	4-6
<b>Morphine solution</b> (Oramorph)	2-4	0.5-1.0	4	1	10	3-4
<b>Morphine controlled release</b> (MS Contin)	2-4	1.0	8-12	1	15	8-12
<b>Fentanyl</b> (Durogesic)	1-6	12-24	48-72	100	0.025-0.050/hr	48-72

# Paracetamol + Codeine

- Mild-moderate pain or severe pain (with contraindications for NSAIDs)
- Possible use in association with major analgesic drugs
- Up to 10% of population are poor metabolizers (i.e., little / no analgesia from codeine)
- Rapid metabolizers also may have little analgesic effect

Dose adults / children > 40 kg:

**500-30 mg/6 h – 1000 mg-60 mg/8 h (max 3g-180mg)**

Dose children 30-40 kg:

**500 mg-30 mg /8 h**

# Morphine

- 10 mg / mL vials for i.v. administration
- Peak in 5 min; half-life: 10 min

Dose adults / children:

**1° bolus: 0.1 mg / kg**

**2° bolus (after 10 min): 0.05 mg / kg**

Dose elderly-renal insufficiency-hepatic insufficiency:

**1° bolus: 0.05 mg / kg**

**2° bolus (after 10 minuti): 0.0025 mg / kg**

- Oral morphine (tablets): 10 – 30 – 60 – 100 mg PR / oral solution: 10 – 30 – 100 mg / 5 mL
- Histamine release !

# Fentanyl-1

- 0.1 mg / 2 mL vials for i.v. administration; rapid onset and very short half-life
- Peak in 5 min; half-life: 10 min

Dose (i.v. = intranasal; adults = children),

NO ADJUSTMENT IN HEPATIC OR RENAL INSUFFICIENCY:

**1° bolus: 1.5 mcg / kg**

**2° bolus (after 10 min): 0.75 mcg / kg**

Dose in the elderly:

**1° bolus: 0.75 mcg / kg**

**2° bolus (after 10 min): 0.35 mcg / kg**

- Side effects → avoidable with administration of a rapid bolus diluted in 0.9% saline solution

# Fentanyl-2

- Transdermal patch for constant analgesia
- Transdermal patch 12 mcg / h – 25 mcg / h – 50 mcg / h – 75 mcg / h - 100 mcg / h
- Titration with adjustment of 12 / 25 mcg / h - change patch every 72 h

Oral Morphine 24 h (mg/day)	Fentanyl t-dermal patch dose (mcg/h)
< 44	12
45 - 89	25
90 - 149	50
150 - 209	75
210 - 269	100
270 - 329	125
330 - 389	150
390 - 449	175
450 - 509	200
510 - 569	225
570 - 629	250
630 - 689	275
690 - 749	300

# Oxycodone

- Oral administration (dosing interval 12 h)
- Tablets 5 - 10 - 20 - 40 - 80 mg

Initial dose: 5 mg x 2 / day + on demand therapy with oral morphine  
(Oramorph 10 mg) max 4 / day

- Dose adjustment ( 5 mg) every 24 h if need for Oramorph > 2 / day
- 10 mg oral oxycodone = 20 mg oral morphine


# Tolerance and dependence

## Tolerance

- Pharmacologic effect characteristic of opioids
- With regular use, opioids become less effective over time and tolerance develops
- Tolerance does not develop to pupil constriction and constipation
- Higher dose are needed to achieve the same effect

## Dependence

- Development of physiological / psychological adaptation in response to long term use
- A chronic , relapsing condition associated with physical changes in the brain due to frequent use
- Experience cravings and withdrawal symptoms when the effects of opioids begin to wear off



**Side effects**

# Acute opioid intoxication/overdose

## Signs and symptoms

Disruption of central control of peripheral sympathetic activity

Respiratory depression → apnea

Circulatory depression → hypotension

Constricted pupils (maybe dilated with meperidine)

Convulsions with meperidine and propoxyphene

Arrhythmias with propoxyphene

Pulmonary edema

Reduced reflexes

CNS depression

Drowsiness → sedation → coma

## Treatment



### Naloxone

0.4 mg intravenously and repeated as necessary

Short duration of action, 1-2hrs


Give every 30mins until patient is stable

# Opioid induced bowel dysfunction




# PEG / Macrogol: (Almost) All you wanted to know in...

↓ transit  
(> left vs. right colon)



Corazziari E.S., et al., *Dig Dis Sci*  
1996; 41:1636-42

Global, long-term  
efficacy in constipation




Ford AC & Suares NC.,  
*Gut* 2011;60:209-218

Binding water  
=  
Iso-osmotic effect



Schiller L.R., et al.,  
*Gastroenterology* 1988;94:933-41



1<sup>st</sup> line-therapy in many  
patient subtypes




De Giorgio R., et al.,  
*Eur Rev Med Pharmacol Sci* 2011;  
15:960-66

No major adverse events

Well tolerated  
(bloating, flatulence  
may occur)

Corazziari E.S., et al.,  
*Gut* 2000; 46: 522-526

PEG no electrolytes =  
PEG + electrolytes




Seinela L., et al.,  
*Drugs Aging* 2009; 26:703-13

# Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs)

Currently available therapeutics:

**Methylnaltrexone (6 trials)\*; Alvimopan (4 trials); Naloxone (4 trials); Naloxegol (2 trials)**

- Antagonize peripheral constipating effect of opioids
- Restricted ability to cross BBB
- No effect on analgesia



*for review see: Camilleri M., et al., Neurogastroenterol Motil 2014;26(10):1386-95*


\* FDA approved


# Types of available prokinetics


Drug	D <sub>2</sub> antag	5-HT <sub>4</sub> ago	5-HT <sub>3</sub> antag	Colinest Inib.	Mot R ago	Dominant Effect(s)
<b>Anticholinesterases</b>						
Neostigmine	-	-	-	+++	-	GI prokinetic
Pyridostigmine	-	-	-	+++	-	
<b>Antidopaminergic*</b>						
Domperidone	+++	-	-	-	-	Antiemetic; prokinetic (UGI)
<b>Antidopaminergic** serotonergic</b>						
Metoclopramide	+++	+	+	-	-	Antiemetic; prockinetic (UGI)
Sulpiride	+++	+	±	-	-	Antiemetic; prokinetic (UGI)
Clebopride	+++	?	?	-	-	Antiemetic; prokinetic (UGI)
Itopride	+++	-	-	++	-	Prokinetic (UGI)
<b>Serotonergic</b>						
Prucalopride	-	+++	-	-	-	Enterokinetic

\* Butyrophenone derivatives; \*\* Benzimidazole derivatives

# WHO pain ladder










**Somatic**


**Viscerale**


**Referito**







































## Punti e segni appendicolari


- punto di Mc Burney (1)
- punto di Morris (2)
- punto di Munro (3)
- punto di Lanz (4)
- punto di Clado (5)
- punto di Jalaguier (6)
- segno di Rovsing  
(dolore ds alla compressione a sn)
- segno dell'ileo-psoas  
(sollevamento coscia contro  
pressione di mano opponente)
- segno dell'otturatore  
(adduzione della coscia flessa contro  
pressione di mano opponente)














## Punti renali

- punto costo-muscolare (5)
- punto costo-lombare (6)
- punto costo-vertebrale (7)















## AREA DI TRAUBE



**AREA DI TIMPANISMO** E' dovuta alla proiezione del fondo gastrico sulla parete costale


### LOCALIZZAZIONE:


- 1) VI cartilagine costale SX
- 2) IX cartilagine costale
- 3) Linea ascellare anteriore


Larga 12cm circa


Alta 10cm circa


Grande importanza diagnostica assume la scomparsa dell'area di timpanismo.













# VARIAZIONI DELL'AREA DI OTTUSITA' EPATICA

L'area di ottusità epatica può variare nel senso di:

- aumento
- riduzione
- spostamento
- scomparsa



AIA DI TRAUBE



percussione anteriore del  
fegato (sull'emiclaveare)

massima ampiezza  
dell'area di ottusità:

**10** cm.


(9 - 12)




percussione laterale  
del fegato (lungo la  
linea ascellare ant.)


massima ampiezza  
dell'area di  
ottusità:

**7** cm.









**FLUIDO LIBERO NELLA CAVITA' PERITONEALE.**





**FLUIDO CONTENUTO ENTRO LE ANSE INTESTINALI**
















FLUIDO LIBERO NELLA CAVITA' PERITONEALE.





## LIQUIDO ASCITICO



















Posizione genu-pettorale



Posizione genu-gomitale



Posizione laterale di Sims





}


}


}


}

















Fig. 717 - Ritenzione acuta. La vescica si estende fino all'ombelico.





N.B.


QUANDO IL COLON E' SPASTICAMENTE  
CONTRATTO, L'ESAMINATORE,  
DISPONENDO LE DITA  
PERPENDICOLARMENTE AL TRATTO  
INTERESSATO, PALPERA' LA CORDA  
COLICA





REPERTO FREQUENTE NELLA  
SD DELL'INTESTINO IRRITABILE












































•


•



•


•


•


•


























































Endoscope inserted into mouth


Endoscope travels through gastrointestinal tract until reaching point of blockage





Gallstone seen through endoscope


ADAM.























































# Il valore dell'anamnesi (ανά μνεσις)...ma quale anamnesi ?

- **Anamnesi patologica prossima:**

Motivo del ricovero in PS, Reparto, della visita ambulatoriale, etc

Non sempre facile stabilire una netta separazione tra APR e APP...  
(sintomi direttamente riconducibili alla patologia pregressa)

**Sintomi !!!! Fondamentale chiedere:** quando ?  
come ? Acutamente o più gradualmente ?  
caratteristiche ? Continuo...o periodico ?  
intensità ?  
è in relazione con atti fisiologici ? Postura ?

Se il sintomo è il «dolore»: sede, irradiazione, caratteri, tipologia  
quando è comparso ? A digiuno ? Dopo aver mangiato

C'è febbre ?

# Acute pain

- **AMI**
- **Trigeminal nevralgia**
- **Migraine**
- **Renal colic**
- **Herpes zooster (VZV)**

# Possible sites of alterations in gut sensitivity

